Posted by Michael Wonder on 18 Feb 2019
Novo Nordisk, Lilly, Sanofi must face insulin drug pricing suit
16 February 2019 - Judge says diabetics can proceed with consumer-fraud claims.
Novo Nordisk and two other insulin makers must face claims they gouged diabetes patients through deceptive price lists for their life saving drugs.
U.S. District Judge Brian Martinotti in New Jersey on Friday allowed a proposed class-action lawsuit filed by 67 diabetics against Novo, Eli Lilly and the U.S. unit of French drugmaker Sanofi to proceed on consumer-fraud allegations tied to skyrocketing insulin prices. The judge threw out the plaintiffs’ racketeering claims.
